Elevated plasma platelet activating factor,platelet activating factor acetylhydrolase levels and risk of coronary heart disease or blood stasis syndrome of coronary heart disease in chinese:A case control study

Inflammation

Volumn 35, Issue 4, 2012, Pages 1419-1428

  Zheng, Guo Hua ^a   Xiong, Shang Quan ^b   Mei, Li Juan ^a   Chen, Hai Ying ^a   Wang, Ting ^b   Chu, Jian Feng ^a  

^a FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b People's Hospital of Fujian   (China)

Author keywords

Blood stasis syndrome; Coronary heart disease; Platelet activating factor; Platelet activating factor acetylhydrolase; Risk factor

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; C REACTIVE PROTEIN; INTERLEUKIN 6; THROMBOCYTE ACTIVATING FACTOR;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD STASIS SYNDROME; CHINESE; CONTROLLED STUDY; CORONARY RISK; FEMALE; HEMATOLOGIC DISEASE; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHINA; CORONARY DISEASE; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PLATELET ACTIVATING FACTOR; QUESTIONNAIRES; RISK FACTORS;

EID: 84866729024     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-012-9455-4     Document Type: Article

References (48)

1. Ross, R. 1999. Atherosclerosis: an inflammatory disease. The New England Journal of Medicine 340(2): 115-126.
2. Blake, G.J., and P.M. Rider. 2002. Inflammatory bio-markers and cardiovascular risk prediction. Journal of Internal Medicine 252: 283-294.
3. Welch, E.J., R.P. Nalkawadi, Z. Li, P. Lin, S. Ishii, et al. 2009. Opposing effects of platelet-Activating factor and lyso-platelet activating factor on neutrophil and platelet activation. Molecular Pharmacology 75: 227-234.
4. Uhlig, S., R. Goggel, and S. Engel. 2005. Mechanisms of plateletactivating factor (PAF)-mediated responses in the lung. Pharmacological Reports 57(suppl): 206-221.
5. Vadas, P., M. Gold, B. Perelman, and G.M. Liss. 2008. Plateletactivating factor, PAF acetylhydrolase, and severe anaphylaxis. The New England Journal of Medicine 358: 28-35.
6. Xu, W., S.H. Xia, H. Wang, H. Chen, and Y.L. Wang. 2007. Role of platelet activating factor in pathogenesis of acute respiratory distress syndrome. Chinese Medical Journal 120: 1840-1844.
7. Karasawa, K. 2006. Clinical aspects of plasma platelet-Activating factor-Acetylhydrolase. Biochimica et Biophysica Acta 1761: 1359-1372.
8. Zalewski, A., and C. Macphee. 2005. Role of lipoproteinassociated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arteriosclerosis, Thrombosis, and Vascular Biology 25: 923-931.
9. Ai, M., and M. Madjid. 2009. Lipoprotein-Associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target. Future Cardiology 5: 159-173.
10. Morgan, E.N., E.M. Boyle, W. Yun, and J.C. Kovacich. 1999. Platelet-Activating factor acetylhydrolase prevents myocardial ischemia-reperfusion injury. Circulation 100(19suppl): ll365-368.
11. Chris, J., D.S. Packard, S.J. Denis, and M.D. Reily. 2000. Lipoprotein-Associated phospholipase A2 as an independent predictor of coronary heart disease. The New England Journal of Medicine 343: 1148-1155.
12. Magjid, M., M. Ali, and J.T. Willerson. 2010. Lipoproteinassociated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature. Texas Heart Institute Journal 37: 25-39.
13. Karbina, S.A., and E. Ninio. 2006. Plasma PAF-Acetylhydrolase: an unfulfilled promise? Biochimica et Biophysica Acta 1761: 1351-1358.
14. Howard, K.M., M. Abdel, M. Ditmyer, and N. Pate. 2011. Lipopolysaccharide and platelet-Activating factor stimulate expression of platelet activating factor acetylhydrolase via distinct signaling pathways. Inflammation Research 60: 735-744.
15. Chen, K.J., M. Xue, and H. Yin. 2008. The relationship between platelet activation and coronary heart disease and blood-stasis syndrome. Journal of Capital Medical University 29: 266-269.
16. Ren, J.X., J.X. Liu, C.R. Lin, et al. 2010. Comparative analysis on the biological basis of blood stasis syndrome induced by qistagnation and qi-deficiency in patients with unstable angina pectoris. Chinese Journal of Integrated Traditional and Western Medicine. 30: 352-356.
17. Pen, W.J., Z.H. Xing, X. Liao, and W.P. Liu. 2011. Effect of Yiqi Huoxue therapy on serum IL-6, ICAM-1 and TNF-A in patients with stable angina pectoris in qi deficiency and blood stasis. Journal of Traditional Chinese Medicine University of Hunan. 31: 49-51.
18. Zhao, H.Y., W.H. Wang, W.Q. Chen, et al. 2011. Effect of Shanzha Xiaozhi capsule on homocysteine and hypersensitivity-C reactive protein in patients of non-Acute coronary heart disease with phlegm and blood stasis syndrome. Journal of New Chinese Medicine 43: 9-11.
19. Ma, X.J., H.J. Yin, and K.J. Chen. 2007. Research progress of correlation between blood stasis syndrome and inflammation. CJITWM 27: 669-672.
20. Chignard, M., J.P. Le Couedic, M. Tence, B.B. Vargaftig, and J. Benveniste. 1979. The role of platelet-Activating factor in platelet aggregation [J]. Nature 279: 799-800.
21. International Society of Cardiology. 1981. Naming and diagnostic criteria of ischaemic heart disease. Chinese Journal of Cardiology 9: 75-76.
22. Disease Special Committee, Chinese Association of the Integrative Medicine. Standard of syndrome differentiation on coronary heart disease of Chinese medicine. Chinese Journal of Integrated Traditional and Western Medicine (Chin), 1991; 11:257.
23. Hanahan, D.J. 1986. Platelet activating factor: a biologically active phosphoglyceride. Annual Review of Biochemistry 55: 483-509.
24. Penna, C., E. Bassino, and G. Alloatti. 2011. Platelet activating factor: the good and bad in the ischemic/reperfused heart. Experimental Biology and Medicine 236: 390-401.
25. Montrucchio, G., G. Alloatti, and G. Camussi. 2000. Role of plateletactivating factor in cardiovascular pathophysiology. Physiological Reviews 80: 1669-1699.
26. Gilli, U.O., M.K. Schneider, P. Loetscher, et al. 2005. Human polymorphonuclear neutrophils are recruited by porcine chemokines acting on CXC chemokine receptor 2, and platelet-Activating factor. Transplantation 79: 1324-1331.
27. Subbanagounder, G., N. Leitinger, T. Peggy, and K.F. Shih. 1999. Evidence that phospholipids oxidation products and/or platelet activating factor play an important role in early atherogenesis: in vitro and in vivo inhibition by WEB 2086. Circulation Research 85: 311-318.
28. Feng, W., T. Wu, Q.F. Sun, P.S. Yang, and X.L. Liu. 2010. Detection of platelet activating factor in unstimulated mixed saliva and gingival crevicular fluid of periodontitis patients with coronary heart disease. Shanghai Kou Qiang Yi Xue 19: 228-231.
29. Chen, H., P. Zheng, J. Zhu, and L. Zhao. 2010. Platelet-Activating factor levels of serum and gingival crevicular fluid in nonsmoking patients with periodontitis and/or coronary heart disease. Clinical Oral Investigations 14: 629-636.
30. Garber, A.M., and A.L. Avins. 1994. Triglyceride concentration and coronary heart disease. BMJ 309: 1440-1442.
31. Oppenheimaer, G.M. 2006. Profiling risk: the emergence of coronary heart disease epidemiology in the United States. International Journal of Epidemiology 35: 720-730.
32. Weber, C., and H. Noels. 2011. Atherosclerosis: current pathogenesis and therapeutic option. Nature Medicine 17: 1410-1422.
33. Xue, M., K.J. Chen, and H.J. Yin. 2008. Relationship between platelet activation related factors and polymorphism of related genes in patients with coronary heart disease of blood stasis syndrome. Chinese Journal of Integrative Medicine 14: 267-273.
34. Tsantila, N., A.B. Tsoupras, E. Fragopoulou, and S. Antonopolou. 2011. In vitro and in vivo effects of stains on platelet-Activating factor and its metalism. Angiology 62: 209-218.
35. Snyder, F. 1989. Biochemistry of PAF: a unique class of biologically active phospholipids. Proceedings of the Society for Experimental Biology and Medicine 190: 125-135.
36. Maseri, A. 1997. Inflammation, atherosclerosis, and ischemic events: exploring the hidden side of the moon. The New England Journal of Medicine 336: 1014-1016.
37. Chen, Y.Z. 2006. The changed concentration of serum IL-6, IL-10 and CHD. Chinese Journal of Microecology. 18: 222-223.
38. Ren, N., T. Huang, J. Shu, J.B. Du, et al. 2007. Changes and prognostic value of serum high sensitivity C reactive protein and interleukin 6 levels in patients with acute coronary syndrome. Acta Academiae Medicinae CPAPF. 16: 497-501.
39. Pasceri, V., J.T. Willerson, and E.T. Yeh. 2000. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102: 2165-2168.
40. Zheng, F., D. Qu, H. Xu, et al. 2009. Relationship between Chinese medicine syndrome and serum level of high-sensitivity Creactive protein in patients with stable coronary heart disease. CJJIWM 29: 485-489.
41. Arai, H. 2002. Platelet-Activating factor acetylhydrolase. Prostaglandins & Other Lipid Mediators 68-69: 83-94.
42. Macphee, C.H., K.E. Moores, H.F. Boyd, D. Dhanak, et al. 1999. Lipoprotein-Associated phospholipase A2, platelet-Activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochemical Journal 338: 479-487.
43. Tjoelker, L.W., and D.M. Stafforini. 2000. Platelet-Activating factor acetylhydrolases in health and disease. Biochimica et Biophysica Acta 1488: 102-123.
44. Itabe, H. 1998. Oxidized phospholipids as a new landmark in atherosclerosis. Progress in Lipid Research 37: 181-207.
45. Carlquist, J.F., J.B. Muhlestein, and J.L. Anderson. 2007. Lipoprotein-Associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Review of Molecular Diagnostics 7: 511-7.
46. Caslake, M.J., C.J. Packard, K.E. Sucking, S.D. Holmes, et al. 2000. Lipoprotein-Associated phospholipase A2 platelet-Activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150: 413-419.
47. Samsamshariat, S., G. Basati, A. Movahedian, M. Pourfarzam, and N. Sarrafzadegan. 2011. Elevated plasma platelet-Activating factor acetylhydrolase activity and its relationship to the presence of coronary artery disease. Journal of Research in Medical Sciences 16: 674-679.
48. Persson, M., J.A. Nilsson, J.J. Nelson, B. Hedblad, and G. Berglund. 2007. The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a populationbased cohort. Atherosclerosis 190: 388-396.